Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness. Methods: One hundred twenty-five incident prostate cancer cases and 125 age-matched controls were sampled from among participants in the original San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort study. The odds ratios (OR) of prostate cancer and high-grade disease (Gleason sum >7) associated with the WHO categories of body mass index (kg/m2) and with tertiles of serum concentrations of adiponectin, leptin, and IL-6 were estimated using multivariable conditional logistic regression models. Results: Body mass index was not associated with either incident prostate cancer [obese versus normal; OR, 0.75; 95% confidence interval (95% CI), 0.38-1.48; Ptrend = 0.27] or high-grade versus low-grade disease (OR, 1.17; 95% CI, 0.39-3.52; Ptrend = 0.62). Moreover, none of the three adipokines was statistically significant associated with prostate cancer risk or high-grade disease, respectively: leptin (highest versus lowest tertile; OR, 0.77; 95% CI, 0.28-1.37; Ptrend = 0.57; OR, 1.20; 95% CI, 0.48-3.01; Ptrend = 0.85); adiponectin (OR, 0.87; 95% CI, 0.46-1.65; Ptrend = 0.24; OR, 1.93; 95% CI, 0.74-5.10; Ptrend = 0.85); IL-6 (OR, 0.84; 95% CI, 0.46-1.53; Ptrend = 0.98; OR, 0.84; 95% CI, 0.30-2.33; Ptrend = 0.17). Conclusions: Findings from this nested case-control study of men routinely screened for prostate cancer and who had a high prevalence of overweight and obesity do not provide evidence to support that prediagnostic obesity or factors elaborated by fat cells strongly influence prostate cancer risk or aggressiveness. However, due to the small sample population, a small or modest effect of obesity and adipokines on these outcomes cannot be excluded. (Cancer Epidemiol Biomarkers Prev 2006;15(7):1331–5)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“Obesity, a major public health problem in the United States (1, 2), is associated with several diseases, including cancer (1, 3).”
BackgroundSubcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor- , in Vivo
Mohamed-Ali, V. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4196 · Cited by 717
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460 · cited 1×
“Finally, IL-6 is an adipokine that regulates immune response and is also associated with cell growth, cell differentiation, and angiogenesis (24, 29, 30).”
BackgroundSelf-citationShariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261 · cited 2×
“In prostate cancer patients, elevated circulating IL-6 levels have been associated with advanced disease stage, distant metastasis, metastasis-related morbidity, and decreased overall survival (29, 33-35).”
Background
Cited by
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, M., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 640
Obesity and Prostate Cancer: Weighing the Evidence
Allott, E. H., Masko, E. M., & Freedland, S. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.11.013 · Cited by 601
Obesity, metabolic syndrome, and prostate cancer
Hsing, A. W., Sakoda, L. C., & Chua, S. C. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.843s · Cited by 344
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence
Barb, D., Williams, C. J., Neuwirth, A. K., & Mantzoros, C. S. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.858s · Cited by 338
Obesity and cancer: Symposium on ‘Diet and cancer’
Pischon, T., Nöthlings, U., & Boeing, H. (2008) · Proceedings of the Nutrition Society · doi:10.1017/s0029665108006976 · Cited by 320
Metadata
- Authors
- Baillargeon, J., Platz, E. A., Rose, D. P., Pollock, B. H., Ankerst, D. P., Haffner, S., Higgins, B., Lokshin, A., Troyer, D., Hernandez, J., Lynch, S., Leach, R. J., & Thompson, I. M.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2006-07-01
- Volume
- 15
- Issue
- 7
- Pages
- 1331-1335
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2112387917
- Cited by
- 132
- References
- 4
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study. https://app.cochat.ai/papers/10.1158/1055-9965.epi-06-0082
- The paper
- Baillargeon, J., Platz, E. A., Rose, D. P., Pollock, B. H., Ankerst, D. P., Haffner, S., Higgins, B., Lokshin, A., Troyer, D., Hernandez, J., Lynch, S., Leach, R. J., & Thompson, I. M. (2006). Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-06-0082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.